HK inno.N releases K-Cab in Singapore

The S.Korean homegrown new drug for GERD; sixth overseas sale after China, Mongolia, the Philippines, Mexico, Indonesia

HK inno.N releases K-Cab in Singapore
Ji-Hyun Lee 1
2023-09-04 15:32:20 bluesky@hankyung.com
Bio & Pharma


South Korean bio-health company HK inno.N announced on Monday that it has released the new drug K-CAB for gastroesophageal reflux disease (GERD) in Singapore and held a commemorative symposium for local medical professionals.

With this launch, K-CAB has now been introduced in Singapore, following China, Mongolia, the Philippines, Mexico, and Indonesia.

K-CAB is a P-CAB (potassium-competitive acid blocker) class medication for treating GERD and has received approval as a 30th domestically developed new drug.

Local distribution is managed by United Italian Trading Corporation (UITC), a pharmaceutical marketing distribution company in Singapore. HK inno.N exports the finished product to UITC, which then handles local sales and marketing.

"The average annual growth rate of the pharmaceutical market in Singapore over the past three years has been 11%, making it one of the standout growth countries among major Southeast Asian nations," CEO of HK inno.N Kwak Dalwon said. "We will continue to collaborate closely with our local partners to ensure the successful overseas approval and launch of K-CAB."

Write to Ji-Hyun Lee at bluesky@hankyung.com
#HK inno.N #K-CAB #gastroesophageal reflux disease #GERD #P-CAB #potassium-competitive acid blocker #UITC

HK inno.N releases new drug for GERD in Indonesia

HK inno.N releases new drug for GERD in Indonesia

South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in Indonesia, the largest market in Southeast Asia.HK inno.N announced on Monday that it has launched the GERD drug K-CAB (generic name: Tegoprazan) in

HK inno.N's GERD drug K-CAB gets approval in Mexico

HK inno.N's GERD drug K-CAB gets approval in Mexico

HK Inno.N's K-CAB South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegoprazan) has been approved by the Mexican Ministry of Health. This marks the first approval of the treatment in a Latin American cou

HK inno.N to introduce biosimilars for bone disease treatment from Spain

HK inno.N to introduce biosimilars for bone disease treatment from Spain

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to introduce biosimilars of bone loss treatment Prolia and Xgeva.Under the terms of the agreement, HK inno.N plans to apply for permits by acquiring dome

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, will receive insurance coverage in China.According to industry sources on Thursday, K-CAB Tab was included in the National Reimbu

HK inno.N gets approval to sell K-CAB in Singapore

HK inno.N gets approval to sell K-CAB in Singapore

HK inno.N's K-CAB South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux disease (GERD), from Singaporian authorities.K-CAB is the 30th domestic new drug released by HK inno.N in 2019 and is a new potass
(* comment hide *}